Serum Proteomics and Plasma Fibulin-3 in Differentiation of Mesothelioma From Asbestos-Exposed Controls and Patients With Other Pleural Diseases

INTRODUCTION: Malignant pleural mesothelioma (MPM) is difficult to diagnose. An accurate blood biomarker could prompt specialist referral or be deployed in future screening. In earlier retrospective studies, SOMAscan proteomics (Somalogic, Boulder, CO) and fibulin-3 seemed highly accurate, but SOMAs...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsim, Selina, Alexander, Laura, Kelly, Caroline, Shaw, Ann, Hinsley, Samantha, Clark, Stephen, Evison, Matthew, Holme, Jayne, Cameron, Euan J., Sharma, Davand, Wright, Angela, Grundy, Seamus, Grieve, Douglas, Ionescu, Alina, Breen, David P., Paramasivam, Elankumaran, Psallidas, Ioannis, Mukherjee, Dipak, Chetty, Mahendran, Cox, Giles, Hart-Thomas, Alan, Naseer, Rehan, Edwards, John, Daneshvar, Cyrus, Panchal, Rakesh, Munavvar, Mohammed, Ostroff, Rachel, Alexander, Leigh, Hall, Holly, Neilson, Matthew, Miller, Crispin, McCormick, Carol, Thomson, Fiona, Chalmers, Anthony J., Maskell, Nick A., Blyth, Kevin G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514249/
https://www.ncbi.nlm.nih.gov/pubmed/34116230
http://dx.doi.org/10.1016/j.jtho.2021.05.018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514249/
https://www.ncbi.nlm.nih.gov/pubmed/34116230
http://dx.doi.org/10.1016/j.jtho.2021.05.018

Ejemplares similares